Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.30 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17351832 | 1.00 | GRIN2B (0.47) | GRIN2BGRIN2CJAK3DDR1CDK4 | |
| SCHEMBL20130471 | 0.89 | GRIN2B (0.37) | GRIN2BGRIN2C | |
| SCHEMBL15937215 | 0.88 | GRIN2B (0.32) | GRIN2BGRIN2C | |
| SCHEMBL15937177 | 0.88 | GRIN2B (0.32) | GRIN2BGRIN2C | |
| SCHEMBL17359172 | 0.87 | JAK3 (0.33) | GRIN2BGRIN2CJAK3 | |
| SCHEMBL15937172 | 0.87 | JAK3 (0.33) | GRIN2BGRIN2CJAK3 | |
| SCHEMBL17359176 | 0.86 | GRIN2B (0.47) | GRIN2BGRIN2CJAK3DDR1 | |
| SCHEMBL17351830 | 0.86 | GRIN2B (0.47) | GRIN2BGRIN2CJAK3DDR1 | |
| SCHEMBL17351861 | 0.86 | GRIN2B (0.49) | GRIN2BGRIN2CJAK3DDR1CDK4 | |
| SCHEMBL19129129 | 0.84 | JAK3 (0.40) | GRIN2BGRIN2CJAK3TSHRNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-05-10 | — | — | US | disclosed |
| US-9708335-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | Apytinyx Inc. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708335-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | Apytinyx Inc. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150368254-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
| US-20150368254-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885JAK3 4606/4885 |
| US-20150368254-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | GRIN2B 5/4885GRIN2C 4/4885JAK3 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.